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Abstract
Aim: Disruption of the intestinal mucosal tolerance, that is, the immunological unre-
sponsiveness to innocuous food antigens and the commensal microbiota, in the colon 
is associated with several chronic diseases including inflammatory bowel disease 
(IBD). Understanding the mechanisms responsible for intestinal mucosal tolerance 
has potential translational value for its therapy and management. Human intestinal 
mesenchymal cells (iMCs) play important roles in colonic mucosal tolerance, but 
further studies on their tissue regenerative and immunomodulatory capacities are nec-
essary in order to fully understand their function in health and disease.
Methods: In this study, we have isolated and analysed the capacity of human iMCs 
to promote wound healing and modulate immune responses in vitro and in vivo, using 
the dextran sulfate sodium (DSS)- induced colitis model.
Results: Cultured iMCs were CD45−CD73+CD90+CD105+ and accelerated the 
wound closure in a normal colon mucosa (NCM) 356 human epithelial cell wound 
healing assay. Furthermore, iMCs blocked the LPS- mediated induction of TNF- α in 
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1 |  INTRODUCTION
Inflammatory bowel disease (IBD) is a chronic idiopathic 
disease mainly represented by two major forms, ulcerative 
colitis (UC) and Crohn's disease (CD). Although its etiology 
remains unknown, IBD is thought to stem from a combination 
of environmental factors, genetic predisposition, microbiota 
imbalance, and mucosa immune defects.1 Both conditions are 
thought to start after a breach of the intestinal epithelial bar-
rier, leading to excessive and sustained cytokine production 
and immune cell recruitment and activation.2
Mesenchymal stromal cells (MSCs) are nonhematopoi-
etic, nonepithelial, nonendothelial, multipotent cells with 
self- renewal capacity present in almost all tissues and organs.3 
In the last decade, mounting evidence has shown that they 
possess the ability to repair damaged and inflamed tissues 
and although not considered “professional” immune cells, 
they can regulate immune responses through direct contact 
or by secreting soluble mediators.4- 7 Intestinal mesenchymal 
cells (iMCs) represent a heterogeneous cell population which 
includes MSCs, fibroblasts, myofibroblasts and pericytes. 
These cells reside in the subepithelial compartment where 
they provide much of the structural framework of the intes-
tine. Importantly, iMCs regulate the homeostasis/mainte-
nance of the epithelial barrier8,9 and promote immunological 
tolerance against the commensal bacteria and food antigens 
through the expression of immunomodulatory molecules, in-
cluding programmed death- ligand- 1 (PD- L1),10 chemokines 
and retinoic acid.11
However, recent studies have suggested that iMCs play 
important roles in both inhibiting and promoting intestinal 
inflammation and damage in IBD. Using a murine model of 
acute dextran sulfate sodium (DSS) colitis, Scheibe et al12 
showed that IL- 36- receptor signaling in iMCs promoted the 
mucosal healing in vivo. In contrast, recent studies using 
single- cell RNA sequencing have identified a subset of 
pro- inflammatory iMCs which increase drastically in the in-
flamed intestine of both pediatric and adult UC patients.13,14 
This remodeling of the colonic mesenchyme in IBD patients 
is thought to perpetuate the intestinal inflammation and pre-
vent the repair of the intestinal barrier.
Due to their important homeostatic function in the healthy 
intestine and their ambiguous role in intestinal inflammation 
during IBD, further analysis of their capacity to promote ep-
ithelial repair and regulate immune/inflammatory responses 
is of great importance when designing new therapies for in-
testinal inflammatory diseases. In the present study we have 
isolated iMCs from human colonic biopsies and demonstrate 
their ability to promote wound healing and regulate immune 
responses in vitro and in vivo, using a model of DSS- induced 
colitis. Our data show that human iMCs isolated from non-
inflamed intestine possess tissue- regenerative and immuno-
modulatory capacities that could potentially be potentiated/
restored in order to reduce IBD disease severity.
2 |  RESULTS
2.1 | Cultured iMCs show a fibroblast- like 
morphology and express CD73, CD90, CD105 
and PD- L1
iMCs isolated from intestinal resections presented a 
fibroblast- like shape upon in vitro culture (Figure 1A) and 
lacked hematopoietic (CD45), epithelial (CD31, EpCam) 
and endothelial (CD34) markers, while expressing PD- L1 
(CD274), CD73 (ecto- 5′- nucleotidase), CD90 (thymocyte 
differentiation antigen 1) and CD105 (endoglin, a surface 
membrane glycoprotein part of the TGF- β receptor complex) 
(Figure 1B). These last markers are also expressed by MSCs 
and are transmitted to their mesenchymal lineage descend-
ants, such as muscle cells and fibroblast.15 This phenotype 
de Andalucía through the contract “Nicolás 
Monardes” (C- 0013- 2018). A. R- N is a 
postdoctoral fellow from the Instituto de 
Salud Carlos III (Miguel Servet program 
[CP19/00191]). CIBER- EHD is funded by 
the Instituto de Salud Carlos III.
THP- 1 macrophages and inhibited the proliferation of peripheral blood mononuclear 
cells, partly through the induction of indoleamine- 2,3- dioxygenase. In DSS colitic 
mice, iMCs administration reduced the disease activity index and ameliorated intestinal 
tissue damage and permeability. Furthermore, iMCs reduced intestinal inflammation, 
evidenced by a decreased mRNA expression of pro- inflammatory cytokines, reduced 
IL- 1β secretion by intestinal explants and inhibited colonic iNOS protein expression.
Conclusions: Our data show that human iMCs isolated from the noninflamed intes-
tine possess tissue- regenerative and immunomodulatory capacities that could poten-
tially be harnessed/restored in order to reduce IBD severity.
K E Y W O R D S
dextran sulfate sodium colitis, immunomodulation, inflammatory bowel disease, intestinal 
mesenchymal cells, wound healing
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was stable across serial cell passages (from P1- 2 to P7- 8), 
being PD- L1 the only cell marker that was significantly de-
creased at a later passage (Figure 1C).
2.2 | iMCs inhibit T cell proliferation, partly 
through IDO
We first aimed to study the immunomodulatory charac-
teristics of iMCs, beginning with analysing their effect on 
T cell proliferation. MSCs need to be “licensed” by IFN- γ 
and inflammatory cytokines, including TNF- α, to acquire 
suppressive capacities.16,17 Thus, we co- cultured differ-
ent concentrations of nonstimulated and TNF- α/IFN- γ- pre- 
stimulated iMCs with carboxyfluorescein succinimidyl ester 
(CFSE)- labeled peripheral blood mononuclear cells (PBMCs) 
in the presence of the T cell mitogen phytohemagglutinin- L 
(PHA- L) (Figure 2A). In the PHA- L- stimulated cultures, the 
iMCs significantly inhibited the proliferation of CD4+ and 
CD8+ T cells at the highest cell concentration (20000 iMCs) 
(Figure  2B,C). Cytokine- primed iMCs had a significantly 
increased capacity to inhibit the proliferation of CD4+ T 
cells, with a similar trend seen for the suppression of CD8+ 
T cells (Figure 2B,C). Indoleamine- 2,3- dioxygenase (IDO), 
prostaglandin E2 (PGE2) and IL- 10 have been implicated in 
the immunomodulatory capacity of MSCs.18 TNF- α/IFN- γ- 
stimulation of iMCs resulted in a rapid increase in the mRNA 
expression of both IDO and cyclooxygenase (COX)- 2, a key 
enzyme involved in the production of PGE2 (Figure 2D). To 
analyse the role of IDO and PGE2 in the iMCs- mediated in-
hibition of T cells, we added 1- MT (1- methyl tryptophan) 
and indomethacin, which are specific inhibitors of IDO and 
COX- 1/2 activity, respectively (Figure 2E). We observed a 
small, but significant, reduction in the suppressive capacity 
F I G U R E  1  Phenotypic characterization of human iMCs. (A) Morphology of iMCs, 24 and 72 h after isolation through plastic adherence (black 
lines represent 50 μm). At passage 3 (P3), the cultures consisted of homogeneously larger fibroblastic cells (white line represent 20 μm). (B) P2- 3 
iMCs were stained for epithelial (EpCam, CD31), endothelial (CD34), hematopoietic (CD45), mesenchymal (CD73, CD90, CD105) markers, and the 
immunomodulatory marker PD- L1 (CD274) and analyzed by flow cytometry. Representative histograms demonstrate specific staining and the vertical 
lines represent the background staining using the corresponding isotype controls. (C) Average expression levels (% of positive cells in relation to isotype 
control staining) of the above mentioned markers on iMCs at P1- 2 and P7- 8 isolated from 6 donors. Data are shown as mean (SEM). ‡P < .001
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of the iMC in the presence of 1- MT (Figure  2F), but not 
with indomethacin (Figure  2G). Furthermore, the IDO ac-
tivity was assessed in the cell cultures by determining the 
concentrations of tryptophan (Figure 2H, left graph) and its 
metabolite L- kynurenine (Figure 2H, middle graph) in the su-
pernatants. We found that the IDO activity, as defined by the 
L- kynurenine/tryptophan ratio, was significantly increased in 
the PBMC:iMC co- cultures in comparison to PBMCs alone 
(Figure 2H, right graph). As expected, the addition of 1- MT 
significantly reduced the IDO activity. These data further 
suggest a role of iMC- derived IDO in their inhibition of T 
cell proliferation.
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2.3 | iMCs inhibit the LPS- induced 
expression of TNF- α in THP- 1 macrophages
To evaluate the effect of iMCs on macrophage function, 
we pretreated THP- 1 macrophages with iMCs or their con-
ditioned media (iMC- CM), and measured the expression of 
anti- inflammatory and pro- inflammatory cytokines upon li-
popolysaccharide (LPS) stimulation. As shown in Figure 3, 
iMCs stimulated with LPS (1  µg  mL−1) secreted low con-
centrations of TNF- α, whereas TNF- α secretion from THP- 1 
cells was highly increased after LPS stimulation. In contrast, 
THP- 1 cells cultured in the presence of iMCs or iMC- CM 
produced significantly less TNF- α upon LPS stimulation 
(Figure 3A). On the other hand, the expression levels of IL- 
10 were not found to be significantly different between the 
groups (Figure 3B). Furthermore, IFN- γ/TNF- α stimulation 
of iMCs resulted in the induction of several genes involved in 
the polarization of macrophages into anti- inflammatory M2 
macrophages, including TNFα- stimulated gene- 6 (TSG- 6), 
hepatocyte growth factor (HGF) and IL- 6,19 suggesting their 
possible involvement in the observed reduction in TNF- α 
production by THP- 1 cells (Figure 3C).
2.4 | Conditioned media from iMCs 
promotes in vitro wound healing
We next analysed the impact of iMC- CM on human NCM356 
colonic epithelial cells migration/proliferation, using an in 
vitro scratch wound healing assay. We found that the wound 
closure, at 24 and 48 hours after wounding, was significantly 
accelerated in iMC- CM- treated wells when compared with 
the control (DMEM) (Figure 4A,B). In addition, we found 
that stimulation of iMCs with TNF- α/IFN- γ rapidly induced 
the gene expression of tumor progression locus- 2 (TPL- 2) 
(Figure 4C). These data are in agreement with the proposed 
role of TPL- 2 in maintaining epithelial cell homeostatic re-
sponses by increasing its proliferation.20
2.5 | iMCs ameliorate DSS- induced 
acute colitis
Once the immunosuppressive and wound- healing activities 
of iMCs were confirmed in vitro, we sought to analyse their 
effect in an experimental model of acute intestinal inflam-
mation induced by DSS, which displays human IBD- like 
clinical, histopathological and immunological features. In 
this model, the DSS disrupts the intestinal epithelial barrier, 
resulting in the exposure of the submucosa to various luminal 
antigens and activation of the cells mainly involved in the in-
nate immune response.21 Oral administration of 3% (w/v) of 
DSS during five consecutive days resulted in a progressive 
increase in disease activity index (DAI) values, characterized 
by sustained weight loss and excretion of diarrhoeic/bleeding 
faeces. However, mice treated with a systemic administra-
tion of iMCs one day after the initiation of the DSS- treatment 
showed a reduced DAI score (Figure 5A), diminished body 
weight loss (Figure 5B), a less pronounced increase in spleen 
weight (Figure  5C) but with no apparent reduction in the 
colon weight/length ratio (Figure  5D). Nevertheless, the 
iMC- treated mice showed a significant reduction in the histo-
logical damage of the colon (Figure 5E). Representative im-
ages of the histological examination of colonic tissue stained 
with alcian blue, haematoxylin and eosin showed the effect 
of iMCs on DSS- induced colitis In the DSS group we could 
see changes in the mucosa with areas of ulceration (black 
arrow) on the epithelial layer, in addition to a lower number 
of goblet cells and depleted of mucins (yellow arrow), and 
an intense inflammatory cell infiltrate (white arrow). In the 
iMCs group we found an improvement of the colonic histol-
ogy with a reduced area of ulceration, more abundance of 
F I G U R E  2  iMCs inhibit T cell proliferation in vitro. CFSE- labeled PBMCs were stimulated with PHA- L in the presence or absence of 
increasing numbers of nonstimulated or TNF- α/IFN- γ pre- stimulated iMCs. Six days later, cells were acquired on a BD FACsAria™ IIIu cell sorter 
and the proliferation of CD4+ and CD8+ T cells was quantified using the FlowJo software. (A) Representative histograms showing CFSE- dilution 
of PHA- L- activated CD4+ T cells cultured with or without nonstimulated iMCs. (B) Proliferation index of CD4+ T cells cultured in the presence of 
nonstimulated (white bars) and TNF- α/IFN- γ pre- stimulated (blue bars) iMCs. Percentage of CFSE control refers to CFSE levels in PBMCs alone, 
stimulated with PHA- L at day 6. Data are shown as mean (SEM) of 3 independent experiments. *P < .05 and ‡P < .001 vs “0 iMCs”, *P < .05. 
(C) Proliferation of CD8+ T cells cultured in the presence of nonstimulated (white bars) and TNF- α/IFN- γ pre- stimulated (blue bars) iMCs. Data 
are shown as mean (SEM) of 3 independent experiments. *P < .05 and †P < .01 vs “0 iMCs”. (D) iMCs were stimulated with TNF- α/IFN- γ 
for 1, 2, 6 and 24 h and mRNA expression of IDO (left graph), Cox- 2 (middle graph) and il- 10 (right graph) were measured by qPCR. Data are 
shown as mean (SEM) of three independent experiments. *P < .05 vs “0”. (E) Representative histograms showing CFSE- dilution of CD4+ T cells 
cultured with 20 000 iMCs in the absence or presence of 1- MT. Proliferation index of CD4+ T cells co- cultured with 20 000 iMCs under standard 
(SD) conditions (blue bars), or with the addition of (F) 1- MT, or (G) indomethacin (grey bars). Data are shown as mean (SEM) of 6 independent 
experiments. *P < .05. (H) Supernatants from the cell cultures were collected on day 6 and the concentrations of tryptophan (left graph) and L- 
kynurenine (middle graph) were determined by UHPLC- MS/MS. After that, the L- kynurenine/tryptophan ratio (right graph) was calculated. Data 
are shown as mean (SEM) of 6 independent experiments
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goblet cells and a diminished infiltration of inflammatory 
cells (Figure 5F).
2.6 | iMC administration protects the 
integrity of the intestinal barrier in DSS- 
treated mice
To characterize the effects of the iMCs on the impaired co-
lonic epithelial permeability in colitic mice, intestinal bar-
rier function was determined by oral administration of 4 kDa 
FITC- dextran. As shown in Figure 6A, colitic mice suffered 
a significant increase in intestinal permeability in compari-
son with the control group. However, this epithelial barrier 
impairment was significantly reduced in the iMCs- treated 
group. Additionally, the mRNA expression of proteins 
involved in the maintenance of epithelial integrity, includ-
ing zonula occludens- 1 (Zo- 1) and villin was significantly re-
duced in the DSS group in comparison with the control mice, 
whereas the iMC- administration significantly increased ex-
pression of these markers (Figure 6B,C). To further investi-
gate the mechanisms behind this iMC- mediated protection of 
the intestinal barrier, we analysed the amount of proliferation 
(Ki67 immunofluorescence) and apoptosis (TUNEL assay) 
of cells in intestinal tissue sections from the control, DSS 
and DSS + iMCs groups. To our surprise, we found an in-
creased number of Ki67+ cells in the DSS mice compared to 
the iMC- treated group, although the difference was not sta-
tistically significant (Figure 6D,E). In addition, the TUNEL 
assay showed a significant increase in apoptotic cells in the 
intestine of iMC- treated mice in comparison to DSS colitic 
mice (Figure 6E,G).
F I G U R E  3  iMCs inhibit macrophage activation in vitro. PMA- activated THP- 1 cells were cocultured with 100 000 iMCs or treated with iMC- 
CM for 48 h. Cells were subsequently cultured without (white bars) or with LPS (blue bars) for 24 h and the levels of TNF- α (A) and IL- 10 (B) in 
the culture supernatants were analyzed by ELISA. ‡P < .001 vs DMEM (+LPS) group. (C) iMCs were stimulated with TNF- α/IFN- γ for 1, 2, 6 
and 24 h and mRNA expression of Tsg- 6 (left graph), Hgf (middle graph) and Il- 6 (right graph) was measured by qPCR. Data are shown as mean 
(SEM) of 3 independent experiments. *P < .05, †P < .01 vs “0”
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2.7 | iMC administration reduces 
inflammatory responses in colitic mice
The biochemical analysis of the colonic tissue corroborated 
the intestinal anti- inflammatory effect of iMCs, revealing 
the positive impact on the altered colonic immune response 
induced by DSS. DSS- induced colitis was characterized 
by increased expression of the pro- inflammatory cytokines 
Tnf- α, Il- 6 and Il- 12, as well as the adhesion molecule 
Icam- 1, and Inos (Figure 7A- E). iMC administration signifi-
cantly reduced the expression of these cytokines, whereas 
only a trend in reducing Icam- 1 expression was observed 
(Figure  7D). We also analysed the expression of the M2 
macrophage- related gene ArgI (Figure 7F). Although ArgI 
expression was highest in DSS- treated mice, the ratio ArgI/
Inos was increased, albeit not significantly, in iMC- treated 
mice suggesting a possible polarization towards an anti- 
inflammatory M2 macrophage response (Figure 7G).22 The 
intestinal anti- inflammatory activity exerted by iMCs was 
also corroborated when the pro- inflammatory inducible en-
zyme iNOS was evaluated by Western blot. In contrast to 
healthy control animals, mice from the DSS group showed 
an increased expression of this enzyme in colon. However, 
the systemic administration of iMCs significantly down- 
regulated the colonic expression of iNOS (Figure  7H,I). 
Additionally, protein levels of the pro- inflammatory cy-
tokine IL- 1β were measured in culture supernatants of co-
lonic explants by ELISA. IL- 1β levels were significantly 
lower in the iMCs- treated colitic group when compared with 
the DSS control group (Figure 7J).
3 |  DISCUSSION
In the intestine, epithelial cells and iMCs create a physical 
barrier, effectively separating the microbiome from the un-
derlying tissues and immune system.8 Although it is well 
documented that iMCs play important roles in intestinal 
health and disease, the true nature of their immunomodula-
tory capacity is not clear and warrants further research. The 
aim of the current study has been to characterize the tissue 
regenerative and immunomodulatory capacities of human 
iMCs in vitro and in vivo.
Evidence suggests that iMCs derived from bone marrow- 
derived gremlin+ MSCs.23 Although the phenotype of MSCs 
and their derivatives from different tissues is similar, their 
differentiation capacity, gene expression, and secretomes 
are distinct and partly reflect their tissue/organ- specific 
function.24,25 Importantly, MSCs and iMCs retain their tis-
sue specific characteristics through multiple passages in 
vitro26,27 making it feasible to study, at least to some extent, 
their tissue- specific properties in vitro. In our study, we have 
isolated iMCs based on plastic adherence, resulting in the 
selection of a heterogeneous collection of fibroblastic cells, 
including fibroblasts and myofibroblasts. After 2- 3 pas-
sages in vitro these cells adopted a homogenous phenotype 
(CD31−CD34−EpCam−CD45−CD73+CD90+CD105+), sim-
ilar to that of MSCs from bone marrow and adipose tissue,28,29 
which was maintained in culture upon serial passaging.
Several reports have shown a role of human iMCs in in-
testinal immune tolerance. Firstly, human colonic myofibro-
blasts promote intestinal tolerance through the expansion 
F I G U R E  4  iMC- conditioned medium (CM) promotes wound closure in the NCM356 human colonic epithelial cell scratch assay. (A) 
Representative phase contrast images of NCM356 epithelial cell layers cultured in DMEM (control) or iMC- CM from two individual donors 
(iMC#69, iMC#71) were taken at 0, 24 and 48 h after wounding (black line represents 200 μm). (B) Scratch wound closure was calculated as 
described in materials and methods. Data are shown as mean (SEM) of 4 independent experiments, ‡P < .001 vs control. (C) iMCs were stimulated 
with TNF- α/IFN- γ for 1, 2, 6 and 24 h and mRNA expression of Tpl- 2 was measured by qPCR. Data are shown as mean (SEM) of 3 independent 
experiments. *P < .05, ‡P < .001 vs “0”
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F I G U R E  5  Treatment with iMCs ameliorates DSS- induced acute colitis. Mice (n = 10) received 3% DSS in the drinking water ad libitum 
from day 0 to day 4. iMCs (106/mouse) were injected intraperitoneally (n = 10) on day 1. Mice receiving tap water were used as controls (n = 10). 
(A) Disease activity index (DAI) and (B) weight loss index was determined daily. (C) Spleen weight was determined on day 5. (D) Colon 
length/weight ratios determined on day 5. (E) Histological evaluation of control, DSS and iMC- treated mice. Data are shown as mean (SEM) 
of 5- 6 individual mice/group. *P < .05 vs DSS mice. (F) Representative histological images of colonic tissue stained with alcian blue (mucins), 
haematoxylin and eosin showing the effect of iMCs on DSS- induced colitis (the black arrow indicates areas of ulceration, the yellow arrow 
indicates the loss of goblet cells and decrease in mucins, and the white arrow indicates an intense inflammatory cell infiltrate)
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F I G U R E  6  iMCs promote the integrity of the intestinal epithelial barrier in colitic mice. (A) Gut permeability was determined on day 5 by 
measuring the plasma concentration of FITC- dextran. Expression of the epithelial integrity proteins (B) Zonula occludens- 1 (Zo- 1) and (C) Villin 
was quantified by qPCR. Fold- changes are expressed as mean (SEM). *P < .05, †P < .01, ‡P < .001 vs DSS mice. (D) Representative images 
showing immunofluorescence staining of Ki67 (proliferation) in colonic tissue sections. Ki67+ cells are shown in green and nuclei are shown 
in blue (Hoechst). White bars represent 100 μm. (E) Data show Ki67+ cells/crypt and are represented as mean (SEM) of 5 mice/group. ns., not 
significant. (F) Representative images of TUNEL- stained (apoptosis) colonic tissue sections from control, DSS and iMCs- treated mice. Apoptotic 
cells are stained in green and nuclei in blue (Hoechst). (G) Data show TUNEL+ cells/field, and are represented as mean (SEM) of 5 mice/group. 
‡P < .001 vs DSS mice
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F I G U R E  7  iMCs inhibit DSS- induced inflammation in colitic mice. Total RNA was extracted from colons of control, DSS- and iMC- treated 
mice on day 5 and the gene expression of (A) Tnf- α, (B) Il- 6, (C) Il- 12, (D) Icam, (E) Inos and (F) ArgI were analyzed by qPCR. *P < .05, †P < .01, 
‡P < .001 vs DSS mice. (G) Based on the qPCR results, the ArgI/Inos ratio was calculated. Data are shown as mean (SEM) of 10 mice/group of 
two separate experiments. (H) Colonic iNOS protein expression was evaluated by Western blot. The arrow indicates the iNOS monomer with 
a molecular mass of 130 kDa. (I) Densitometric analysis of the corresponding bands. (J) IL- 1β protein levels in culture supernatants of colonic 
explants from control, DSS- , and iMC- treated mice were measured by ELISA. *P < .05 vs DSS mice
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of CD4+CD25highFoxp3+ regulatory T cells.30 Secondly, 
human colonic CD90+ stromal cells express PD- L1 and 
PD- L2 which they use to suppress the proliferation of 
CD45RA+CD4+ T cells in a cell contact– dependent man-
ner.28 We found that iMCs could inhibit the proliferation of 
PBMCs (both CD4+ and CD8+ T cells) induced by PHA- L. 
Pre- stimulation of iMCs with TNF- α and IFN- γ increased 
their immunosuppressive capacity in vitro, which correlated 
with an induction of Ido1 mRNA expression. Furthermore, 
we found a significant increase in IDO enzyme activity in 
the PBMC:iMC co- cultures. IDO is a well- known IFN- γ- 
inducible inhibitor of T cell proliferation used by human bone 
marrow MSCs.31 In IBD, IDO is highly up- regulated in the 
inflamed intestinal mucosa and TLR9- mediated induction 
of IDO protects against experimental colitis.32 However, to 
our knowledge, no study has analysed the function of IDO in 
iMCs. Our data demonstrate that iMCs can use IDO to inhibit 
T cell proliferation. However, the inhibition of IDO did not 
result in a complete reversion of suppression, indicating that 
iMCs use additional mechanisms to inhibit T cell responses. 
Interestingly, we found that some iMC cell lines depended to 
a higher degree on IDO, suggesting that their immunomod-
ulatory capacity and its underlying mechanisms vary with 
donor, and most likely, experimental conditions.33
Although iMCs have been shown to promote mucosal tol-
erance, several reports have highlighted a pro- inflammatory 
role of iMCs in IBD. Kinchen and colleagues observed a 
remodeling of the colonic mesenchyme in IBD patients 
characterized by the emergence of a pro- inflammatory iMC 
population which prevented epithelial healing and promoted 
disease.13 Furthermore, West and colleagues showed that 
oncostatin M (OCM) is up- regulated in IBD patients com-
pared to healthy controls which induces a pro- inflammatory 
response in intestinal stromal cells.34 Importantly, high levels 
of OCM correlated with a decreased responsiveness to anti- 
TNF- α therapy. Recently, Martin et al,35 and Smillie et al36 
characterized inflammatory cell modules in the affected in-
testinal mucosa of CD and UC patients which associate with 
resistance to anti- TNF- α therapy. In addition to epithelial and 
immune cells, these modules contained inflammatory iMCs 
with the ability to recruit monocytes to the site of inflam-
mation. Monocytes/macrophages play important roles in 
the pathogenesis of IBD37 and recent data suggest that anti- 
TNF- α monoclonal antibodies exert their beneficial effect 
on IBD through the induction of immunomodulatory mac-
rophages.38 Bone marrow and adipose tissue- derived MSCs 
have previously been shown to induce anti- inflammatory 
macrophages which ameliorate experimental sepsis and 
colitis.39,40 However, few studies have analysed the effect of 
human iMCs on macrophage polarization41 and to this end 
we employed the human leukemia monocytic THP- 1 cell 
line which is an adequate model for analysing macrophage 
polarization into the M1 and M2 activation states.42,43 We 
show that iMCs as well as their conditioned medium inhib-
ited the LPS- induced production of TNF- α by THP- 1- derived 
macrophages. How iMCs reduce the production of TNF- α by 
THP- 1 macrophages is not known. We found that TNF- α/
IFN- γ induced the expression of several genes involved in 
the polarization of M2 macrophages, including TSG- 6, HGF 
and IL- 6.19 However, additional studies are necessary to spe-
cifically evaluate the involvement of these factors in the im-
munomodulatory function of iMCs. Further insight into how 
iMC can induce anti- inflammatory macrophages could help 
in re- educating the inflammatory iMC populations that ap-
pear in IBD patients.
Due to the dual role of iMCs in regulating immune re-
sponses we decided to analyse the anti- inflammatory and 
epithelial regenerative capacity of iMC in vivo, using the 
DSS- model of acute intestinal inflammation in C57BL/6J 
mice. This experimental model resembles the main manifes-
tations of IBD, concretely this model has been used to study 
the innate immune mechanisms in intestinal inflammation 
and simulates human IBD by promoting an exaggerated Th2 
immune response.44 We injected the iMCs intraperitoneally 
since this route has proven the most adequate based on thera-
peutic efficacy and migration of MSCs towards the inflamed 
intestine.45,46 We show for the first time that injection of iMC, 
one day after the start of DSS administration, significantly de-
creased the colitis severity and weight loss. Injection of iMCs 
resulted in a reduction of colonic inflammation, evidenced by 
a decreased immune infiltration and down- regulation of in-
flammatory mediators in the colon. In addition, we observed 
an increment, although not significant, in the ArgI/Inos ratio, 
suggesting a polarization of macrophages towards an M2 re-
sponse, which is in agreement with our in vitro results using 
THP- 1 cells. These data are in accordance with the anti- 
inflammatory effects seen using MSCs from different tissues 
in experimental colitis47 and again shows that iMCs from the 
healthy intestine possess immunomodulatory capacity.
We found that administration of iMCs protected the in-
testinal epithelial barrier against the DSS- induced dam-
age, which is in agreement with our observation that the 
iMC- CM can promote wound regeneration in vitro. This is 
also supported by recent studies demonstrating that murine 
CD90+CD34+gp38+ iMCs are important for the maintenance 
of intestinal epithelial stem cells.48,49 One possible media-
tor providing this protection could be PGE2 which is known 
to stimulate epithelial growth, inhibit epithelial apoptosis 
during insults and potentiate WNT- signaling.50,51 However, 
we found higher levels of proliferating (Ki67+) cells in the 
colons of DSS mice compared to iMC- treated mice which is 
in contrast to studies showing an increased intestinal epithe-
lial proliferation after MSC administration to colitic mice.52 
Nevertheless, several studies have demonstrated that DSS- 
induced epithelial damage is followed by a compensatory in-
crease in epithelial cell proliferation.53- 56 Consequently, our 
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data suggests that, in our experiments, iMC administration 
does not promote intestinal barrier integrity by promoting ep-
ithelial cell proliferation, but rather protecting against DSS- 
induced tissue damage.
We thus proceeded to evaluate the extent of apoptosis 
in the colonic tissue in our experimental groups. Although 
there was an increase in TUNEL- positive/apoptotic cells be-
tween healthy and DSS- treated mice, we unexpectedly found 
a significantly higher number of TUNEL- positive cells in the 
iMC- treated group compared to DSS mice. Although surpris-
ing, this is in agreement with several studies demonstrating 
that MSCs, via IDO57 or FAS- L58 can induce apoptosis of 
T cells, playing a pivotal role in their ability to ameliorate 
colitis.58,59 In addition, it has also been reported that MSC- 
derived membrane particles can induce selective apoptosis 
of pro- inflammatory monocytes.60 Although our data show 
that iMC administration results in a clear improvement of the 
integrity of the intestinal barrier in colitic mice, further in-
vestigations are needed to understand the mechanisms behind 
this observation.
Interestingly, several recent studies have shown that BM- 
MSCs can be polarized into pro- inflammatory “MSC1” or 
anti- inflammatory “MSC2” phenotypes when primed via 
TLR4 and TLR3, respectively.61,62 Regarding iMCs, Beswick 
recently reported that the expression of PD- L1 on iMCs in 
CD decreases, making them unable to efficiently control 
the pathogenic Th1 responses. Furthermore, TLR4 signal-
ing increased the PD- L1- dependent inhibition of T cells by 
iMCs.10 These data suggest that the microbiota can modulate 
both the tissue regenerative and immunomodulatory capacity 
of iMCs. As the dysbiotic microbiome seen in IBD patients 
has been shown to drive IBD pathogenesis, further studies 
should investigate its effect on immunomodulatory proper-
ties of iMC.
In summary, we have shown that iMCs isolated from 
healthy human intestine promote epithelial wound closure 
and possess the capacity to modulate immune/inflammatory 
responses in vitro and in vivo. Our data might be relevant for 
the development of new therapies targeting the dysregulated 
intestinal stroma in IBD.
4 |  MATERIALS AND METHODS
4.1 | Cell isolation and cultures
Intestinal resections were obtained from patients undergo-
ing surgery in the University Hospital Virgen de las Nieves 
(Granada, Spain). These patients had been previously admit-
ted for bowel resection due to various intestinal pathologies, 
including diverticulitis, benign polyps or colon cancer. iMCs 
were isolated from noncomprised tissue (ie tissue that dis-
tances a minimum of 5 cm from the affected area). All the 
samples were collected with the written consent of each pa-
tient according to the Declaration of Helsinki. The study was 
approved by the local ethics committee and conforms with 
good publishing practice in physiology.63
Freshly isolated intestinal resections were washed thrice 
with PBS supplemented with 2% penicillin/streptomycin 
to remove debris, stools, and erythrocytes. The tissue was 
weighed, cut into small pieces and resuspended in 15  mL 
of HBSS (40- 50  mg tissue mL−1) containing 400 U mL−1 
DNase (Sigma- Aldrich), 500  U mL−1 collagenase type IV 
(Sigma- Aldrich) and 0.09 U mL−1 dispase II (Roche Applied 
System) and incubated for 60 minutes at 37ºC. The digest was 
washed thrice with cold PBS containing 2 mM EDTA and 
filtered through a 70- μm and a 100- μm nylon mesh. Finally, 
cells were resuspended in complete DMEM Advanced 
(Gibco, ThermoFisher Scientific) (containing 10% fetal bo-
vine serum, 2  mM Ultraglutamine (Lonza), 1% penicillin/
streptomycin and 1% amphotericin B) and cultured at 37ºC 
and 5% CO2. Nonadherent cells were removed after 24 hours 
in culture. Adherent cells showed a fibroblast- like morphol-
ogy and were passed to a new culture flask when cultures 
reached 90% confluence. Cells were used at passage 1- 8.
4.2 | Immunophenotypic 
characterization of iMCs
iMCs at passage number 1- 3 and later on at passage number 
7- 8 were harvested using TrypLE (ThermoFisher Scientific), 
washed with PBS and incubated (20 000- 30 000 cells/stain-
ing) with 7- aminoactinomycin D (7- AAD) (Nalgene, Nalgen 
Nunc International Corporation) and FcR blocking reagent 
(Miltenyi Biotec GmbH) for 15 minutes at 4ºC. Cells were 
subsequently stained with the following antibodies: CD45- 
APC- eFluor®780, CD73- PE, CD90- FITC, CD105- Pe- Cy7 
(eBioscience, ThermoFisher Scientific), CD31- FITC, 
EpCam- PerCP- Cy5.5, CD34- APC and PD- L1/CD274- PE 
(BD Biosciences) for 30 minutes at 4ºC. Corresponding iso-
type antibodies were used to evaluate background staining. 
Data were acquired using the BD FACS Canto II flow cytom-
eter (BD Biosciences) and analysed using the Flowjo v10.6.2 
software (FlowJo LLC).
4.3 | T cell suppression assay
iMCs were harvested, treated with mitomycin C (50 μg mL−1, 
Sigma- Aldrich) for 20 minutes at 37ºC and plated at 10 000 
and 20 000 cells/well in flat bottomed 96- well plates. Cells 
were subsequently cultured with or without 3 ng mL−1 TNF- α 
(Peprotech EC Ltd) and 10 ng mL−1 IFN- γ (Peprotech EC 
Ltd) for 24  hours. After that, PBMCs were isolated using 
Lymphoprep™ (StemCell Technologies) and labelled with 
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5 µM CFSE (Sigma- Aldrich) for 12 minutes at 37ºC. Labelled 
PBMCs (200 000 cells/well) and 2.5 µg mL−1 of the T cell 
mitogen PHA- L (eBioscience, ThermoFisher Scientific) 
were added to the iMC cultures. In some experiments, 1- MT 
(1  mM, Sigma- Aldrich) or indomethacin (20  µM, Sigma- 
Aldrich) were added to the cocultures. On day 6, supernatants 
were collected and PBMCs were carefully harvested and 
stained with anti- CD4- PE (BD Biosciences), anti- CD3- APC 
(BioLegend) and Zombie Aqua™ (BioLegend) as viability 
dye. Labelled cells were acquired on a BD FACsAria™ IIIu 
cell sorter (BD Biosciences) and the cell division (prolifera-
tion index based on CFSE signal intensity) of CD4+ and CD8+ 
(CD3+CD4−) T cells was analysed using the FlowJo v10.6.2 
software (FlowJo LLC; Becton, Dickinson and Company).
4.4 | Detection of indoleamine 
2,3- dioxygenase activity by UHPLC– MS/MS in 
conditioned PBMC:iMC supernatants
IDO activity was evaluated by quantifying tryptophan 
and L- kynurenine concentrations in supernatants from 
the PBMC:iMC- cultures on day 6 by UHPLC- MS/MS. 
All chemicals used for quantification were of analytical 
HPLC- MS grade. Water was obtained by purification with a 
Milli- Q system from Millipore. Formic acid and acetonitrile 
for mobile phases were purchased from Scharlab.
UHPLC- MS/MS analysis was performed on a Waters 
Acquity UPLC™ H- Class from Waters. A Xevo TQS tandem 
quadrupole mass spectrometer (Waters) equipped with an or-
thogonal Z- spray™ electrospray ionization (ESI) source was 
used for tryptophan and L- kynurenine detection. Separation 
of compounds was obtained with a BEH (Ethylene Bridged 
Hybrid) column C18 50*2.7  mm 1.7  μm particle size 
(Waters). The compounds were separated using a gradient 
mobile phase consisting of solvent A (LC- MS grade water 
plus 0.1% of formic acid) and solvent B (LC- MS grade aceto-
nitrile plus 0.1% formic acid). Thus, the elution program was 
a multi- step linear gradient at a flow rate of 0.55 mL min−1. 
Gradient conditions were 0.0- 3.0 minutes 1% phase B; 3.0- 
5.0 minutes, 10%- 25% phase B; 5.0- 7.0 minutes, 25%- 90% 
phase B and back to 1% in 0.1 minutes. Total run time was 
11.0 minutes. The injection volume was 10 μL and the col-
umn temperature was maintained at 45ºC.
For mass spectrometric analysis, ESI was performed in 
positive ion mode. The tandem mass spectrometer was op-
erated in the multiple reactions monitoring (MRM) mode. 
Instrument parameters were as follows: capillary voltage, 
2.00  kV; source temperature, 150ºC; desolvation tempera-
ture, 600ºC; cone gas flow, 150 L h−1; desolvation gas flow, 
1000 L h−1; collision gas flow, 0.15 mL min−1, and nebulizer 
gas flow, 7.0 bar. Dwell time was set at 25 ms collision en-
ergies and cone voltages were optimized for both analytes.
In order to quantify the individual content of the ana-
lytes, two calibration curves were prepared using tryptophan 
and L- kynurenine commercial standards (Sigma- Aldrich). 
Concentrations were determined by interpolation in the cor-
responding calibration curve using the peak area. MassLynx 
4.1 software was used for instrument control, peak detection 
and integration.
4.5 | Preparation of the conditioned 
media of iMCs
iMCs from four unrelated donors were seeded in 24- well 
plates at a density of 50 000 cells mL−1. Once they reached 
confluence, the medium was replaced with fresh basal me-
dium and incubated for 48  hours at 37ºC at 5% CO2. The 
iMC- CM were harvested, centrifuged at 500×g, aliquoted 
and stored at −20ºC until use.
4.6 | Anti- inflammatory effect of 
iMCs and their conditioned media in THP- 
1 cells
The human monocytic cell line THP- 1 was maintained in com-
plete RPMI 1640 (Gibco; Thermofisher Scientific). For co- culture 
experiments, THP- 1 cells (250 000 cells mL−1) were first differ-
entiated into adherent macrophages with 50 ng mL−1 of PMA 
(Sigma- Aldrich) in 24- well plates. After 48 hours, human iMCs 
(100 000 cells) or iMC- CM were added to the adherent THP- 1 
macrophages. After 48 hours, cells were stimulated with LPS 
(1 µg mL−1; Sigma- Aldrich) for another 24 hours. Supernatants 
were collected for cytokine determination by ELISA.
4.7 | Scratch wound healing assay
NCM356 human colonic epithelial cells were kindly pro-
vided by Laura Medrano González and Ezra Aksoy (William 
Harvey Research Institute, Queen Mary University of London, 
London, UK). Cells were seeded at 150 000 cells mL−1 in 6- 
well plates. When the cultures had reached confluence, the 
monolayers were scraped in straight lines using sterile 200 μL 
pipette tips in order to create scratch wounds of homogenous 
width. After a wash with PBS, cells were cultured in con-
trol or conditioned media, both diluted 1:1 with fresh basal 
medium. To track the scratch- wound closure, the scratches 
were observed by an inverted microscope (Olympus- CKX41, 
Olympus Europa SE & Co. KG) and equivalent photos were 
taken at 0, 24 and 48 hours. Finally, the scratch area was meas-
ured using the ImageJ software (Free Software Foundation 
Inc). These experiments were performed with iMC- CM pre-
pared from iMCs of 4 different donors.
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4.8 | Induction of colitis with DSS
All animal studies were carried out in accordance with the 
“Guide for the Care and Use of Laboratory Animals” as prom-
ulgated by the National Institute of Health and the protocols 
approved by the Ethic Committee of Laboratory Animals of 
the University of Granada (Spain) (CEEA 17/09/2019/156). 
All the animals were housed in makrolon cages, maintained 
in an air- conditioned atmosphere with a 12- hour light- dark 
cycle and provided with free access to tap water and food. 
Acute colitis was induced in male C57BL/6J mice (7- 9 weeks 
old) (Charles River) by adding 3% DSS (36- 50 KDa, MP 
Biomedicals) from day 0 to day 4 in the drinking water. On 
day 1, mice were injected intraperitoneally (i.p.) with 1 × 106 
human iMCs in 200 μL PBS. The control and DSS groups 
received i.p. injections of 200 µL sterile 1 × PBS. Mice were 
euthanized on day 5.
4.9 | Determination of DAI in DSS- 
induced colitis
The DAI (scale 0- 4) was determined daily by evaluating 
weight loss, stool consistency, and presence of fecal blood 
in each mouse by a blind observer. A score was assigned to 
each one of these parameters according to the criteria pre-
viously proposed.64 Once the animals were euthanized, the 
colons were aseptically removed, rinsed with PBS, weighed, 
and its length was measured under a constant load (2 g). The 
colonic tissue was then sectioned in different fragments for 
subsequent histological and immunological evaluation.
4.10 | In vivo intestinal permeability
The day before sacrifice, mice from the different experi-
mental groups (n = 8/group) were fasted for 12 hours and 
administered FITC- dextran 4 (Sigma- Aldrich) by oral gav-
age (350 mg kg−1 body weight). Four hours after administra-
tion, just before sacrifice, blood was drawn via intracardiac 
puncture and centrifuged at 4000×g for 10 minutes at 4ºC. 
Plasma was diluted (1:10) in PBS and analysed for FITC- 
dextran concentration with a fluorescence spectrophotom-
eter (Fluorostart, BMG Lab Technologies) at an excitation 
wavelength of 485 nm and emission wavelength of 535 nm. 
A standard curve was obtained by serial dilutions of FITC- 
dextran (Sigma- Aldrich) in PBS.65
4.11 | Histological studies
Representative colonic specimens were taken 1 cm from the 
rectum, fixed in 4% paraformaldehyde (PFA), dehydrated in 
15% and 30% sucrose and embedded in OCT. Histochemical 
staining of mucins was performed by incubation of 8  µm 
sections in alcian blue (1%) in acetic acid (3%) for 30 min-
utes prior to conventional hematoxylin and eosin staining. 
Histological damage was evaluated by a blind observer ac-
cording to a previously established scoring system which 
takes into account the presence of ulceration, immune cell 
infiltration, edema and the condition of the crypts.66
4.12 | Assessment of proliferation and 
apoptosis by immunofluorescence
To determine proliferation, cryosections of PFA- fixed OCT- 
included colonic tissue were used to detect Ki67 positive 
cells. Permeabilization and blocking of the samples was 
performed with a solution of 0.1% saponin, 0.05% sodium 
azide and 1% BSA (all from Sigma- Aldrich) in PBS for 
1 hour at room temperature. Then, slides were probed with 
primary polyclonal rabbit anti- Ki67 antibody (1:500 dilu-
tion in blocking buffer, catalog# ab64693 [Abcam]) at 4ºC 
overnight. An anti- rabbit AF488- conjugated secondary an-
tibody (1:1000 dilution catalog# ab150077 [Abcam]) was 
used for signal amplification and detection. Hoechst 33342 
(Invitrogen, ThermoFisher Scientific) was used to stain the 
nuclei. Anti- rabbit IgG isotype control (catalog# 02- 6102, 
Invitrogen, ThermoFisher Scientific) was used as negative 
control. Images were acquired with a Nikon Eclipse Ti- E A1 
confocal microscope (Centre for Scientific Instrumentation, 
University of Granada) equipped with a 20× objective.
Apoptosis was evaluated using the DeadEnd Fluorometric 
TUNEL system (Promega) in colonic tissue sections following 
the manufacturer's indications. Hoechst 33  342 (Invitrogen, 
ThermoFisher Scientific) was used to stain the nuclei. Images 
were acquired with a Leica TCS- SP5 II spectral multiphoton 
confocal microscope (Centre for Scientific Instrumentation, 
University of Granada) equipped with a 20× objective. In 
both cases, acquisition of green channel (positive signals) was 
performed using the 488 nm laser and 505- 550 nm emission 
filter. Quantification of Ki67+ cells per crypt and TUNEL+ 
per field was done using 15 random crypts or 5 random fields 
per slide, respectively. Images were analysed with ImageJ 
software (Free Software Foundation Inc).
4.13 | Colonic explant culture and cytokine 
determination by ELISA
Three whole thick colonic punch biopsies (Miltex) were 
obtained from distal, medial and proximal regions and in-
cubated in 0.5 mL of complete DMEM for 24 hours. After 
that, supernatants were collected and IL- 1β concentration (pg 
mL−1) was measured by ELISA (PeproTech EC Ltd).
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4.14 | Western blot
Representative colonic samples (n = 6) were processed as de-
scribed previously to evaluate iNOS expression by Western 
blotting. Briefly, colonic samples were homogenized (1/5 w/v) 
in PBS supplemented with 0.1% sodium dodecyl sulfate (SDS), 
0.1% sodium deoxycholate, 1% Triton X- 100 and protease 
and phosphatase inhibitors (aprotinin, leupeptin and PMSF) 
(Sigma- Aldrich). Then, 100 µg of protein were boiled at 95ºC 
in 4× Laemmli sample buffer (BioRad) and resolved by sodium 
dodecyl sulphate- polyacrylamide gel electrophoresis (SDS- 
PAGE, 10% polyacrylamide under reducing conditions) and 
electro- transferred to a PVDF membrane (GE Healthcare Life 
Sciences). Membranes were blocked with 3% BSA and probed 
with anti- iNOS (Transduction Laboratories, BD Biosciences) at 
1:500 dilution, 4ºC overnight, followed by 1 hour of incubation 
with peroxidase- conjugated anti- rabbit IgG antibody (1:5000 
dilution) (Sigma- Aldrich) and finally detected with the Western 
Lightning™ Chemiluminescence Reagent Plus (PerkinElmer 
Spain SL). Control of protein loading and transfer was con-
ducted by detection of β- actin levels.66 The quantification of 
bands was performed by densitometric analysis using ImageJ 
software (Free Software Foundation Inc).
4.15 | Analysis of gene expression by  
RT- qPCR
To analyse the effect of proinflammatory cytokines on the 
expression of immunomodulatory mediators by iMCs, cells 
were cultured with or without TNF- α (3 ng mL−1, Peprotech 
EC Ltd) and IFN- γ (10 ng mL−1, Peprotech EC Ltd) for 1, 2, 
T A B L E  1  RT- qPCR primer sequences





Gapdh FW 5′- CCATCACCATCTTCCAGGAG
RV 5′- CCTGCTTCACCACCTTCTTG
Mouse/human 60 NM_001289726.1
Zo- 1 FW 5′- GGGGCCTACACTGATCAAGA
RV 5′- TGGAGATGAGGCTTCTGCTT
Mouse 56 NM_009386.2
Villin FW 5′- CTCCGAGCAGATTGAGAAGG
RV 5′- GGTGCTGCCACTCTTCTACC
Mouse 60 NM_009510.2
Inos FW 5′- GTTGAAGACTGAGACTCTGG
RV 5′- GACTAGGCTACTCCGTGGA
Mouse 56 NM_010927.4
Tnf- α FW 5′- AACTAGTGGTGCCAGCCGAT
RV 5′- CTTCACAGAGCAATGACTCC
Mouse 56 NM_001278601.1
Il- 6 FW 5′- TAGTCCTTCCTACCCCAATTTCC
RV 5′- TTGGTCCTTAGCCACTCCTTC
Mouse 60 NM_031168.2
Icam- 1 FW 5′- GAGGAGGTGAATGTATAAGTTATG
RV 5'- GGATGTGGAGGAGCAGAG
Mouse 60 NM_010493.3
Il- 12 FW 5'- CATCGATGAGCTGATGCAGT
RV 5’- CAGATAGCCCATCACCCTGT
Mouse 59 NM_008351.3
Arg1 FW 5'- TTGCGAGACGTAGACCCTGG
RV 5'- CAAAGCTCAGGTGAATCGGC
Mouse 63 NM_007482.3
Cox- 2 FW 5'- AAGCAGGCTAATACTGATAGG
RV 5'- TGTTGAAAAGTAGTTCTGGG
Mouse 56 NM_000963.4
IDO1 FW 5'- TTGTTCTCATTTCGTGATGG
RV 5'- TACTTTGATTGCAGAAGCAG
Human 56 NM_002164.6
Il- 10 FW 5'- TGGTGAAACCCCGTCTCTAC
RV 5'- CTGGAGTACAGGGGCATGAT
Human 60 NM_001382624.1
Tsg- 6 FW 5'- CCAAATGAGTACGAAGATAACC
RV 5'- CACAGTATCTTCCCACAAAG
Human 55 NM_007115.4
Hgf FW 5'- GCAATTTTTGGTTTGGCTGT
RV 5'- CCTGCCCACAGCATATAGGT
Human 60 NM_001010932.3
Il- 6 FW 5'- GCAGAAAAAGGCAAAGAATC
RV 5'- CTACATTTGCCGAAGAGC
Human 55 NM_001371096.1
Tpl- 2 FW 5'- AACATTGCTGATTCTTCGTG
RV 5'- CCCGAACAAGATTGAAGTAG
Human 55 NM_001320961.2
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6 and 24 hours. Total RNA was extracted using NucleoZOL 
(Macherey- Nagel) following the manufacturer's instructions, 
and reverse transcribed into cDNA using oligo (dT) prim-
ers (Promega). The resulting cDNA was amplified using 
MasterMix qPCR SyGreen (PCR Biosystems Ltd). Detection 
of selected genes was performed on optical- grade 48 well 
plates in an Eco™ Real- Time PCR System (Illumina).
To analyse the expression of inflammatory mediators in 
the colons of control, DSS and iMC- treated DSS mice, total 
colonic RNA was isolated with RNeasy® Mini Kit (Qiagen) 
using a Precellys 24 homogenizer (Bertin Technologies). 
Purity and RNA concentration were measured with a 
NanoDrop™ 2000 spectrophotometer (ThermoFisher 
Scientific) and reverse transcribed (2 μg/sample) using oligo 
(dT) primers (Promega). The resulting cDNA was amplified 
using MasterMix qPCR SyGreen (PCR Biosystems Ltd) in 
optical- grade 48 well plates, employing an Eco™ Real- Time 
PCR System (Illumina). The 2– ΔΔCt method was used to nor-
malize expression results. The values of the housekeeping 
glyceraldehyde- 3- phosphate dehydrogenase (GAPDH) gene 
were used to normalize the values obtained for each of the 
genes. Relative gene expression was calculated by means of 
ΔΔCt formula and expressed as fold- change compared with 
the noncolitic control. Specific primer sequences (Sigma- 
Aldrich) are presented in Table 1.
4.16 | Statistical analysis
Statistical analysis was performed using the GraphPad Prism 
version 7 software (GraphPad Software, Inc). All data are 
represented as mean (SEM) of at least 3 independent ex-
periments/biological replicates unless otherwise stated in 
the figure legends. The Mann- Whitney U test for nonpara-
metric data was used for the analysis of the DAI and mi-
croscopic score. For the PBMCs proliferation experiment 
analysis (Figure 2B,C) a two- way ANOVA followed by the 
Bonferroni post hoc test was performed. For the rest of the 
data, multiple comparisons between groups were performed 
using the one- way ANOVA, followed by the Bonferroni post 
hoc test. A P < .05 was considered significant.
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